Potential X-ALD Oral Therapy, Leriglitazone, Put on Fast Track by FDA
News
Leriglitazone, a potential therapy for X-linked adrenoleukodystrophy (X-ALD), has been put on a fast track for review and possible approval by the U.S. Food and Drug Administration (FDA). Leriglitazone, also ... Read more